Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) Income from Continuing Operations (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Income from Continuing Operations for 15 consecutive years, with 4423000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Income from Continuing Operations fell 17.01% to 4423000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 13920000.0, a 4.28% increase, with the full-year FY2024 number at 14601000.0, down 9.65% from a year prior.
  • Income from Continuing Operations was 4423000.0 for Q3 2025 at Plus Therapeutics, down from 1511000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 1482000.0 in Q2 2023 to a low of 5647000.0 in Q4 2022.
  • A 5-year average of 3799235.29 and a median of 3844000.0 in 2023 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: soared 72.04% in 2023, then plummeted 146.76% in 2024.
  • Plus Therapeutics' Income from Continuing Operations stood at 3694000.0 in 2021, then crashed by 52.87% to 5647000.0 in 2022, then surged by 31.93% to 3844000.0 in 2023, then decreased by 1.53% to 3903000.0 in 2024, then fell by 13.32% to 4423000.0 in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Income from Continuing Operations are 4423000.0 (Q3 2025), 1511000.0 (Q2 2025), and 4083000.0 (Q1 2025).